Investigation, treatment and monitoring of late-onset hypogonadism in males
By Cong-Yi Wang, E. Nieschlag, R. Swerdloff, H. Behre, W. Hellstrom, L. Gooren, Jean Kaufman, Legros Jj, B. Lunenfeld, A. Morales and 5 more. European Journal of Endocrinology, 2008
769 citations recorded by the source corpus.
Demographic data clearly demonstrate that the percentage of the population in the older age group is increasing. Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. Cross-sectional and longitudinal data indicate that the testosterone falls progressively with age and that a significant percentage of men over the age of 60 years have serum testosterone levels that are below the lower limits of young adult (age 20–30 years) men (1–4). The principal questions raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention. The past decade has brought evidence of benefit of androgen treatment of hypogonadal men on multiple target organs and the recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. This has been comprehensively reviewed and summarized by the Institute of Medicine in ‘Testosterone and Aging: Clinical Research Directions’ (5). Long-term data on the effects of testosterone treatment in the older population are limited mainly to effects on body composition and bone mass (6–11). Key questions of the effects of testosterone on patient reported outcomes and functional benefits that may retard physical or mental frailty of the elderly or improve the quality of life are not yet available. Specific risk data on the prostate and cardiovascular systems are needed.
Subfields: Cell Biology, Endocrinology, Diabetes and Metabolism, Pharmacology
View Paper: https://www.semanticscholar.org/paper/1e5729cee1f368d5c29e79047ec2dbae7dd1ef9d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Bhasin
- G. Cunningham
- F. Hayes
- A. Matsumoto
- R. Swerdloff
- Victor M. Montori
- P. Snyder
- V. Basevi
Citations in the corpus
- Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. (2006, background): “Physicians should recognize considerable disagreement among experts on this issue (92).”